Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 112

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 112
---
 consultancy. Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire
and an MBA with Distinction from the Tuck School of Business. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq
listed Company.

Jim Lang’s qualifications to serve on our Board of Directors
are primarily based on his decades of experience as a strategy consultant, broad industry expertise, and senior-level management experience
running several healthcare and information technology companies.

Dr. Amy S. Chappell has served as a director
of the Company since 2025. Since 2024, she has served as CMO of Solaxa Inc., where she oversees clinical development of novel therapies
for ataxia and nerve repair. Prior to that, Dr. Chappell was a clinical trials and neurology consultant for various companies from 2021
to 2024. From 2020 to 2021, she was CMO of Eliem Therapeuetics, assisting it through a successful initial public offering and advancing
programs in epilepsy and mood disorders. Dr. Chappell has also served over 25 years at Eli Lilly & Co., where she played a central
role in developing and gaining US Food and Drug Administration (FDA) approvals for multiple central nervous system indications, including
for Cymbalta® in fibromyalgia and musculoskeletal pain. Dr. Chappell holds a BA from Antioch College and an MD from Indiana University
School of Medicine. She also holds numerous patents, has authored over 100 peer-reviewed publications and presentations, and remains
a Fellow of the American Academy of Neurology.

Dr. Chappell’s qualifications to serve
on our Board of Directors are primarily based on her decades of experience in clinical neuroscience and drug development.

Mr. Kameel D. Farag has served as a director
of the Company since 2025. Most recently, he was Chief Financial Officer, Treasurer and head of business operations at Aspen Neuroscience
from 2021 to 2025, where he oversaw tripling the company’s headcount, secured over $150 million in financing, built manufacturing
infrastructure and prepared the company for clinical data and a potential future public offering. Prior to that, he served as Senior
Vice President, Finance at Ionis Pharmaceuticals from 2018 to 2021. In addition, Mr. Farag spent over 16 years at Amgen Inc. in